Cargando…

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death

Immunoglobulin light-chain (AL) amyloidosis is a rare disease caused by clonal plasma cell secretion of misfolded light chains that assemble as toxic amyloid fibrils, depositing in vital organs including the heart and kidneys, causing organ dysfunction. Plasma cell–directed therapeutics are expected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flanagan, Ken, Kumari, Romika, Miettinen, Juho J., Haney, Staci L., Varney, Michelle L., Williams, Jacob T., Majumder, Muntasir M., Suvela, Minna, Slipicevic, Ana, Lehmann, Fredrik, Nupponen, Nina N., Holstein, Sarah A., Heckman, Caroline A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884539/ https://www.ncbi.nlm.nih.gov/pubmed/35243210 http://dx.doi.org/10.1097/HS9.0000000000000687

Ejemplares similares

PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES
por: Miettinen, Juho, et al.
Publicado: (2023)

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
por: Miettinen, Juho J., et al.
Publicado: (2021)

Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
por: Gebraad, Arjen, et al.
Publicado: (2022)

Prognostic significance of esterase gene expression in multiple myeloma
por: Kumari, Romika, et al.
Publicado: (2021)

P874: DECIPHERING PLASMA CELL HETEROGENEITY AND TUMOR MICROENVIRONMENT IN LIGHT-CHAIN AMYLOIDOSIS USING SINGLE CELL RNA-SEQUENCING
por: Srivastava, A., et al.
Publicado: (2022)

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma
por: Liu, Minxia, et al.
Publicado: (2021)

Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines
por: Schepsky, Alexander, et al.
Publicado: (2020)

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

Melflufen - a peptidase-potentiated alkylating agent in clinical trials
por: Wickström, Malin, et al.
Publicado: (2017)

Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells
por: Haney, Staci L., et al.
Publicado: (2017)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
por: Haney, Staci L., et al.
Publicado: (2022)

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
por: Majumder, Muntasir Mamun, et al.
Publicado: (2017)

Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma
por: Haney, Staci L., et al.
Publicado: (2022)

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
por: Schjesvold, Fredrik H, et al.
Publicado: (2022)

In vitro and in vivo activity of melflufen (J1)in lymphoma
por: Delforoush, Maryam, et al.
Publicado: (2016)

Preclinical activity of melflufen (J1) in ovarian cancer
por: Carlier, Charlotte, et al.
Publicado: (2016)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
por: Strese, Sara, et al.
Publicado: (2016)

P426: HDAC INHIBITORS RESTORE SENSITIVITY TO VENETOCLAX AND NAVITOCLAX IN AML CELLS RESULTING IN THE IRREVERSIBLE DNA DAMAGE
por: Khabusheva, Elmira, et al.
Publicado: (2023)

Disease-related amyloidogenic variants of human lysozyme trigger the unfolded protein response and disturb eye development in Drosophila melanogaster
por: Kumita, Janet R., et al.
Publicado: (2012)

Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
por: Larocca, Alessandra, et al.
Publicado: (2021)

Amyloidogenicity assessment of transthyretin gene variants
por: Grether, Nicolai B., et al.
Publicado: (2022)

P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS
por: Miguel, Enrique Maria Ocio San, et al.
Publicado: (2023)

Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors
por: Haney, Staci L., et al.
Publicado: (2017)

Exploiting heterogeneous features to improve in silico prediction of peptide status – amyloidogenic or non-amyloidogenic
por: Nair, Smitha Sunil Kumaran, et al.
Publicado: (2011)

Targeting HSP90 and monoclonal protein trafficking modulates the unfolded protein response, chaperone regulation and apoptosis in myeloma cells
por: Born, E J, et al.
Publicado: (2013)

Amyloidogenic determinants are usually not buried
por: Frousios, Kimon K, et al.
Publicado: (2009)

The Diagnostic Potential of Amyloidogenic Proteins
por: Jin, Yiyun, et al.
Publicado: (2021)

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
por: Bringhen, Sara, et al.
Publicado: (2021)

Simultaneous Quantitation of Isoprenoid Pyrophosphates in Plasma and Cancer Cells Using LC-MS/MS
por: Chhonker, Yashpal S., et al.
Publicado: (2018)

Transthyretin and BRICHOS: The Paradox of Amyloidogenic Proteins with Anti-Amyloidogenic Activity for Aβ in the Central Nervous System
por: Buxbaum, Joel N., et al.
Publicado: (2017)

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
por: Dunphy, Katie, et al.
Publicado: (2023)

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
por: Tierney, Ciara, et al.
Publicado: (2021)

Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma
por: Haney, Staci L., et al.
Publicado: (2019)

Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin
por: Higaki, Jeffrey N., et al.
Publicado: (2016)

Misfolding of Amyloidogenic Proteins and Their Interactions with Membranes
por: Relini, Annalisa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ok6fkhke7aqkguo1a8qin9to84